Johnson & Johnson (J&J) has announced the completion of its acquisition of V-Wave, a company specialising in the development of heart failure treatments.
V-Wave will now function under the Johnson & Johnson MedTech division.
Go deeper with GlobalData
The acquisition will add the company’s new and minimally invasive Ventura interatrial shunt to the MedTech portfolio.
The strategic move bolsters Johnson & Johnson MedTech’s presence in the cardiovascular market and addresses the critical need for advanced heart failure therapies.
In August 2024, J&J first entered an agreement to acquire the heart failure implant company in a deal that could reach $1.7bn.
The acquisition is expected to enhance J&J’s growth in potential markets and add to its comprehensive medical technology portfolio, which includes solutions for coronary and peripheral artery diseases, heart recovery and atrial fibrillation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt also enables Johnson & Johnson MedTech to deepen its engagement with structural interventional cardiologists and specialists in heart failure treatment.
Johnson & Johnson MedTech worldwide chairman and executive vice-president Tim Schmid stated: “We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech. V-Wave’s novel implantable device, the Ventura interatrial shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction.
“This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”
J&J has disclosed that this transaction is expected to dilute adjusted earnings per share (EPS) by $0.24 in 2024 and by $0.06 in 2025.
The company plans to provide an updated financial outlook for the full year 2024 during its third-quarter earnings report on 15 October 2024.
